Low-dose interleukin-2 as a novel therapeutic option for refractory paraneoplastic neurologic syndrome: a case of chronic relapsing anti-Ma2/Ta paraneoplastic myeloradiculopathy

Seon-Jae Ahn; Han-Sang Lee; Woo-Jin Lee; Kon Chu

doi:10.47936/encephalitis.2021.00038

Low-dose interleukin-2 as a novel therapeutic option for refractory paraneoplastic neurologic syndrome: a case of chronic relapsing anti-Ma2/Ta paraneoplastic myeloradiculopathy

Encephalitis. 2021 Jul;1(3):79-84. doi: 10.47936/encephalitis.2021.00038. Epub 2021 Apr 27.

Authors

Seon-Jae Ahn^{1

2}, Han-Sang Lee^{1

2}, Woo-Jin Lee^{1

2}, Kon Chu²

Affiliations

¹ Center for Hospital Medicine, Seoul National University Hospital, Seoul, Korea.
² Department of Neurology, Comprehensive Epilepsy Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Paraneoplastic neurologic syndromes (PNS) caused by anti-Ma2/Ta antibodies have diverse presentations. Myeloradiculopathy is one anti-Ma2/Ta-associated PNS manifestation. We report the case of a patient with chronic relapsing anti-Ma2/Ta paraneoplastic myeloradiculopathy. The patient was successfully treated with low-dose human recombinant interleukin-2, despite having chronic relapsing symptoms and a refractory response to conventional immunotherapy.

Keywords: Anti-Ma2/Ta paraneoplastic syndrome; Human recombinant interleukin-2; Myeloradiculopathy; Paraneoplastic neurological syndromes.

Publication types

Case Reports